[Intermittent administration of 15-deoxyspergualin for acute on chronic rejection after renal transplantation].
We used 15-deoxyspergualin (DSG) to treat acute on chronic rejection (AOCR) in six kidney transplant recipients. DSG was administered intermittently at a dose of 200-300 mg per body every 2 or 4 weeks for more than 6 months. The efficacy of DSG was evaluated by the changes in serum creatinine values during the rejection therapy. Four (67%) of the six patients responded with the suppression of the increase in serum creatinine values. On the other hand, one patient did not respond at all and developed advanced pancytopenia. These findings suggested that intermittent administration of DSG would be efficient therapy on AOCR in the renal allografts if the patients were treated carefully to prevent severe side effects.
Kawamoto
S
S
Department of Nephrology, Social Insurance Saitama Chuo Hospital.
Kanematsu
E
E
Kanimoto
Y
Y
Kawada
Y
Y
D000208:Acute Disease; D000328:Adult; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006146:Guanidines / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D008297:Male; D010198:Pancytopenia / Q000139:chemically induced
D006146:Guanidines; D007166:Immunosuppressive Agents; D003404:Creatinine; C037258:gusperimus